" /> Envafolimab - CISMeF





Preferred Label : Envafolimab;

NCIt synonyms : Anti-PD-L1 MoAb KN035;

NCIt definition : An injectable formulation of a monoclonal antibody directed against programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274), with immune checkpoint inhibitory and potential antineoplastic activities. Upon subcutaneous administration, envafolimab binds to PD-L1, blocking its binding to and activation of its receptor programmed death 1 (PD-1), which may enhance the T-cell-mediated immune response to neoplasms and reverse T-cell inactivation. PD-L1 is overexpressed by many human cancer cell types. PD-L1 binding to PD-1 on T-cells suppresses the immune system and results in immune evasion. PD-1, a transmembrane protein expressed on activated T-cells, is a negative regulator of the immune system that limits the expansion and survival of CD8 T cells.;

UNII : ES1M06M6QH;

CAS number : 2102192-68-5;

Drug name : Enweida;

Molecule name : KN-035; KN 035;

NCI Metathesaurus CUI : CL512904;

Codes from synonyms : 18741;

Details


Keyword's position in hierarchy(ies) : arborescence

You can consult :


Nous contacter.
09/05/2025


[Home] [Top]

© Rouen University Hospital. Any partial or total use of this material must mention the source.